Document:

Exhibit 4.1

 

WARRANT TO PURCHASE STOCK

 

Company: VG Life Sciences, Inc.

Number of Shares: 3,450,000

Class of Stock: Common

Initial Exercise Price Per Share: $0.45

Issue Date: January 15, 2015

 

THIS WARRANT CERTIFIES
THAT, for the agreed upon value of $1.00 and for other good and valuable consideration, MedBridge Venture Fund, LLC, a California
limited liability company (“Holder”) is entitled to purchase the number of fully paid and nonassessable shares of the
class of securities (the “Shares”) of VG Life Sciences, Inc. (the “Company” or “VGLS”) at the
initial exercise price per Share (the “Warrant Price”) all as set forth above and as adjusted pursuant to Article 2
of this Warrant, subject to the provisions and upon the terms and conditions set forth of this Warrant.

 

ARTICLE 1. EXERCISE

 

1.1Method of Exercise. Holder
may exercise this Warrant by delivering a duly executed Notice of Exercise is substantially the form attached as Appendix 1 to
the principal office of the Company. Unless Holder is exercising the conversion right set forth in Section 1.2, Holders shall also
deliver to the Company a check for the aggregate Warrant Price for the Shares being purchased.

 

1.2Conversion Right. In lieu
of exercising this Warrant as specified in Section 1.1, Holder may from time to time convert this Warrant, in whole or in part,
into a number of Shares determined by dividing (a) the aggregate fair market value of the Shares or other securities otherwise
issuable upon exercise of this Warrant minus the aggregate Warrant Price of such Shares by (b) the fair market value of one Share.
The fair market value of the Shares shall be determined pursuant Section 1.4.

 

1.3No Rights Shareholder. This
Warrant does not entitle Holder to any voting rights as a shareholder of the company prior to the exercise hereof.

 

1.4Fair Market Value. For purposes
of Section 1.2, if the Shares are traded in a public market, the fair market value of the Shares shall be the closing price of
the Shares (or the closing price of the Company’s stock into which the Shares are convertible) reported for the business
day immediately before Holder delivers its Notice of Exercise to the Company. If the Shares are not traded in a public market,
the Board of Directors of the Company shall determine fair market value in its reasonable good faith judgment. The foregoing notwithstanding,
if Holder advises the Board of Directors in writing that Holder disagrees with such determination, then the Company and Holder
shall promptly agree upon a reputable investment banking or public accounting firm to undertake such valuation. If the valuation
of such investment banking firm is greater than that determined by the Board of Directors, then all fees and expenses of such investment
banking firm shall be paid by the company. In all other circumstances, such fees and expenses shall be paid by Holder.

 

    	1

    	 

    

 

1.5Delivery of Certificate and New
Warrant. Promptly after Holder exercises or converts this Warrant, the Company shall deliver to Holder certificates for the
Shares acquired and, if this Warrant has not been fully exercised or converted and has not been fully exercised or converted and
has not expired, a new Warrant representing the Shares not so acquired.

 

1.6 Replacement of Warrants.
On receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant and,
in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory in form and amount to
the Company or, in the case of mutilation, or surrender and cancellation of this Warrant, the Company at its expense shall execute
and deliver, in lieu of this Warrant, a new warrant of like tenor.

 

1.7Repurchase on Sale, Merger, or
Consolidation of the Company

 

1.7.1“Acquisition” 
For the purpose of this Warrant, “Acquisition” means (a) the closing of the sale, transfer or other disposition of
all or substantially all of the VGLS’s assets, (b) the consummation of the merger or consolidation of VGLS with or into another
entity (except a merger or consolidation in which the holders of capital stock of VGLS immediately prior to such merger or consolidation
continue to hold at least fifty percent (50%) of the voting power of the capital stock of VGLS or the surviving or acquiring entity),
or any transaction or series of transactions to which VGLS is a party in which in excess of fifty percent (50%) of VGLS’s
voting power is transferred, or (c) the exclusive license of all or substantially all of the intellectual property of VGLS to a
third party.

 

1.7.2Assumption of Warrant.
Upon the closing of any Acquisition the successor entity shall assume the obligations of this Warrant, and this Warrant shall be
exercisable for the same securities, cash, and property as would be payable for the Shares issuable upon exercise of the unexercised
portion of this Warrant as if such Shares were outstanding on the record date for the Acquisition and subsequent closing. The Warrant
Price shall be adjusted accordingly.

 

1.7.3Purchase Right. Notwithstanding
the foregoing, at the election of Holder, the Company shall purchase the unexercised portion of this Warrant for cash upon the
closing of any Acquisition for an amount equal to (a) the fair market value of any consideration that would have been received
by Holder in consideration of the Shares had Holder exercised the unexercised portion of this Warrant immediately before the record
date for determining the shareholders entitled to participate in the proceeds of the Acquisition, less (b) the aggregate Warrant
Price of the Shares, but in no event less than zero.

 

ARTICLE 2. ADJUSTMENTS TO THE SHARES.

 

2.1Stock Dividends, Splits, Etc.
If the Company declares or pays a dividend on its common stock ( or the Shares if the Shares are securities other than common stock
) payable in common stock, or other securities, subdivides the outstanding common stock into a greater amount of common stock,
or, if the Shares are securities other than common stock, subdivides the Shares in a transaction that increases the amount of common
stock into which the Shares are convertible, then upon exercise of this Warrant, for each Share acquired, Holder shall receive,
without cost to Holder, the total number and kind of securities to which Holder would have been entitled had Holder owned the Shares
of record as of the date the dividend or subdivision occurred.

 

    	2

    	 

    

 

2.2Reclassification, Exchange or
Substitution. Upon any reclassification, exchange, substitution, or other event that results in a change of the number and/or
class of the securities issuable upon exercise or conversion of this Warrant, Holder shall be entitled to receive, upon exercise
or conversion of this Warrant, the number and kind of securities and property that Holder would have received for the shares if
this Warrant had been exercised immediately before such reclassification, exchange, substitution, or other event. Such an event
shall include any automatic conversion of the outstanding or issuable securities of the Company of the same class or series as
the Shares to common stock pursuant to the terms of the Company’s Certificate of Incorporation upon the closing of a registered
public offering of the Company’s common stock. The Company or its successor shall promptly issue to Holder a new Warrant
for such new securities or other property. The new adjustments provided for in this Article 2 including, without limitation, adjustments
to the Warrant Price and to the number of securities or property issuable upon exercise of the new Warrant. The provisions of this
Section 2.2 shall similarly apply to successive reclassifications, exchanges, substitutions, or other events.

 

2.3Adjustments for Combinations,
Etc. If the outstanding Shares are combined or consolidated, by reclassification or otherwise, into a lesser number of shares,
the Warrant price shall be proportionately increased.

 

2.4Adjustments for Diluting Issuances.
The number of shares of common stock issuable upon conversion of the Shares, shall be subject to adjustment, from time to time
in the manner set forth in the Company’s Certificate of Incorporation with respect to issuance of securities for a price
lower than certain prices specified in the Certificate of Incorporation.

 

2.5No Impairment. The Company
shall not, by amendment of its Certificate of Incorporation or through a reorganization, transfer of assets, consolidation, merger,
dissolution, issue, or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of
any of the terms to be observed or performed under this Warrant by the Company, but shall at all times in good faith assist in
carrying out of all the provisions of this Article 2 and in taking all such action as may be necessary or appropriate to protect
Holder’s rights under this Article against impairment. If the Company takes any action affecting the Shares or its common
stock other than as described above that adversely affects Holder’s rights under this Warrant, the Warrant Price shall be
adjusted downward and the number of Shares issuable upon exercise of this Warrant shall be adjusted upward in such a manner that
the aggregate Warrant price of this Warrant is unchanged.

 

2.6Fractional Shares.  No fractional
Shares shall be issuable upon exercise or conversion of the Warrant and the number of Shares to be issued shall be rounded down
to the nearest whole Share. If a fractional share interest arises upon any exercise or conversion of the Warrant, the Company shall
eliminate such fractional share interest by paying Holder amount computed by multiplying the fractional interest by the fair market
value of a full Share.

 

    	3

    	 

    

 

2.7Certificate as to Adjustments.
Upon each adjustment of the Warrant Price, the Company at its expense shall promptly compute such adjustment, and furnish Holder
with a certificate of its Chief Financial officer setting forth such adjustment and the facts upon which such adjustment is based.
The Company shall, upon written request, furnish Holder a certificate setting forth the Warrant price in effect upon the date thereof
and the series of adjustments leading to such Warrant Price.

 

ARTICLE 3. REPRESENTATIONS AND COVENANTS
OF THE COMPANY.

 

3.1Representations and Warranties.
The Company hereby represents and warrants to the Holder that all Shares which may be issued upon the exercise of the purchase
right represented by this Warrant and all securities, if any, issuable upon conversion of the Shares, shall, upon issuance, be
duly authorized, validly issued, fully paid and nonassessable, and free of any liens and encumbrances except for restrictions on
transfer provided for herein or under applicable federal and state securities laws.

 

3.2 Notice of Certain Events.
If the company proposes at any time (a) to declare any dividend or distribution upon its common stock, whether in cash, property,
stock or other securities and whether or not a regular cash dividend; (b) to offer for subscription pro rata to the holders of
any class or series or other rights; (c) to effect any reclassification or recapitalization of common stock; (d) to merge or consolidate
with or into any other corporation, or sell, lease, license, or convey all or substantially all of its assets, or to liquidate,
dissolve or wind up; or (e) offer holders of registration rights the opportunity to participate in an underwritten public offering
of the company’s securities for cash, then, in connection with each such event, the Company shall give Holder (1) at least
20 days prior written notice of the date on which a record will be taken for such dividend, distribution or subscription rights
(and specifying the date on which the holders of common stock will be entitled thereto) or for determining rights to vote, if any,
in respect of the matters referred to in (c) and (d) above; 2 in the case of the matters referred to in (c) and (d) above at least
20 days prior written notice of the date when the same will take place (and specifying the date on which the holders of common
stock will be entitled to exchange their common stock for securities or other property deliverable upon the occurrence of such
event); and (3) in the case of the matter referred to in (e) above, the same notice as is given to the holders of such registration
rights.

 

3.3Information Rights. So long
as the Holder holds this Warrant and /or any of the Shares, the Company shall deliver to the Holder (a) promptly after mailing,
copies of all notices or other written communications to the shareholders of the Company, (b) within ninety (90) days after the
end of each fiscal year of the Company, the annual financial statements of the Company.

    	4

    	 

    

 

 

3.4Registration Under Securities
Act of 1933, as amended.  The Company agrees that the Shares shall be subject to the registration rights granted to any other
holders of the Company’s common stock.

 

ARTICLE 4. MISCELLANEOUS.

 

4.1Term. This Warrant is exercisable,
in whole or in part, at any time and from time to time on or after the fourth anniversary of the Issue Date hereof and up to and
including the fifth anniversary of the Issue Date.

 

4.2Legends.  This Warrant and
the Shares (and the securities issuable, directly or indirectly, upon conversion of the Shares, if any) shall be imprinted with
a legend in substantially the following form:

 

THIS SECURITY HAS NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE SOLD, PLEDGED OR OTHERWISE TRANSFERRED WITHOUT AN
EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT OR PURSUANT TO RULE 144 OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE
CORPORATION AND ITS COUNSEL THAT SUCH REGISTRATION IS NOT REQUIRED.

 

4.3Compliance with Securities Laws
on Transfer. This Warrant and the Shares issuable upon exercise this Warrant (and the securities issuable , directly or indirectly,
upon conversion of the shares, if any) may not be transferred or assigned in whole or in part without compliance with limitation,
the delivery of investment representation letters and legal opinions reasonably satisfactory to the Company, as reasonable requested
by the Company). The Company shall not require Holder to provide an opinion of counsel if the transfer is to an affiliate of Holder
or if there is no material question as to the availability of current information as referenced in rule 144(c), Holder represents
that it has complied with Rule 144(d) and (e) in reasonable detail, the selling broker represents that it has complied with Rule
144(f), and the Company is provided with a copy of Holder’s notice of proposed sale.

 

4.4Transfer Procedure.Subject
to the provisions of Section 4.2, Holder may transfer all or part of this Warrant or the Shares issuable upon exercise of this
Warrant (or the securities issuable, directly or indirectly, upon conversion of the Shares, if any) by giving the Company notice
of the portion of the Warrant being transferred setting forth the name, address and taxpayer identification number of the transferee
and surrendering this Warrant to the company for reissuance to the transferee(s) (and Holder if applicable).

 

4.5Notices. All notices and
other communications from the Company to the Holder, or vice versa, shall be deemed delivered and effective when given personally
or mailed by first-class registered or certified mail, postage prepaid, at such address as may have been furnished to the Company
or the Holder, as the case may be, in writing by the Company or such holder from time to time.

 

    	5

    	 

    

 

4.6Waiver. This Warrant and
any term hereof may be changed, waived, discharged or terminated only by an instrument in writing signed by the party against which
enforcement of such change, waiver, discharge or termination is sought.

 

4.7Attorneys Fees. In the event
of any dispute between the parties concerning the terms and provisions of this Warrant, the party prevailing in such dispute shall
be entitled to collect from the other party all costs incurred in such dispute, including reasonable attorney’s fees.

 

4.8Governing Law.  This Warrant
shall be governed by and construed in accordance with the laws of the State of California, without giving effect to its principles
regarding conflicts of law.

 

 

	 	 
	 	/s/ John P. Tynan
	 	 
	 	By: John P. Tynan
	 	 
	 	Title: President & CEO

 

 

    	6

    	 

    

 

 

APPENDIX 1

 

 

NOTICE OF EXERCISE

 

 

 

1. The undersigned
hereby elects to convert the attached Warrant into in the manner specified in the Warrant. This conversion is exercised with respect
to _______________________ of the Shares covered by the Warrant.

 

 

2.Please issue a certificate or certificates
representing said shares in the name of the undersigned or in such other name as is specified below:

 

	 
	(Name)
	 
	 
	 
	 
	(Address)

 

3.                 
The undersigned represents it is acquiring the shares solely for its own account and not as a nominee for any other party
and not with a view toward the resale or distribution thereof except in compliance with applicable securities laws.

 

	 	 	 
	(Date)	 	(Signature)

 

 

 

    	7Exhibit 10.1

 

CONVERTIBLE PROMISSORY NOTE

AND WARRANT PURCHASE AGREEMENT

 

THIS CONVERTIBLE PROMISSORY NOTE AND WARRANT
PURCHASE AGREEMENT is made as of January 15, 2015, by and among MedBridge Venture Fund, LLC, a California limited liability company
(the “Investor”) and VG Life Sciences Inc. (the "Company" or “VGLS”).

 

THE PARTIES HEREBY AGREE AS FOLLOWS:

 

1.Purchase and Sale of Notes.

 

1.1Purchase and Sale of Note. Subject
to the terms and conditions of this Agreement and pursuant to promissory notes in the form attached hereto as Exhibit A (each a
"Note" and, collectively, the “Notes), the Investor agrees to purchase at the Closing and the Company agrees to
sell and issue to the Investor at the Closing and thereafter Notes in the principal amount of Eight Hundred Sixty Two Thousand
and Five Hundred Dollars ($862,500) at a price equal to one hundred percent (100%) of the principal amount thereof (the "Investment").
This Investment equals the value of services (“Services”) to be provided by Investor or its affiliates to the Company
on or after the Closing, all as such Services are described in Exhibit C hereto. The Warrant (as defined in Section 1.2 below)
includes a cashless exercise feature enabling conversion into unregistered shares (“Shares”) of common stock of VGLS
based on the spread between the warrant exercise price and the then-trading value of the underlying VGLS Shares. The Note is convertible
into Shares at a conversion rate equal to the lowest three-day average closing price of the Shares starting on January 12, 2015
and ending on February 11, 2015 (the “Period”), minus a ten percent (10%) discount. The Note will be convertible into
Shares in four equal tranches (25% each) on the following dates: March 31, 2015, June 30, 2015, September 30, 2015, and December
31, 2015. With respect to the Note: (a) it carries an eight percent (8%) per annum interest rate, (b) any unconverted principal
and interest remaining on the Note on December 31, 2015 shall be automatically converted into Shares on such date, and (c) it will
not be prepayable by VGLS.

 

1.2Purchase and Sale of Warrant.
Subject to the terms and conditions of this Agreement, the Investor agrees to purchase and the Company agrees to sell and issue
to the Investor at the Closing, a warrant in the form attached hereto as Exhibit B (the "Warrant") to purchase shares
of a series of the Company's Common Stock. In addition to the Notes, MVF will receive warrant coverage (“Warrants”)
for four Shares for every one dollar ($1.00) of cash or Services provided to the Company under Section 1.1. above, with each Warrant
to be exercisable by Investor at $0.45 per Share, which includes a cashless exercise feature. The Warrants will be exercisable
on any date from and including the four-year anniversary of the date of this Agreement and the five-year anniversary thereof.

 

1.3Closing.

 

(a)The purchase and sale of the initial
Note and Warrants shall take place at the offices of Investor at 10:00 A.M. between January 12, 2015 and February 11, 2015,
or at such other time and place as the Company and the Investor may determine (the "Closing").

 

    	1

    	 

    

 

 

(b)At the Closing, the Company shall
deliver to the Investor a Note representing the principal amount as is prescribed in Section 1.1 above and the Investor shall
cause to be delivered to the Company a wire transfer to the Company's order in the aggregate amount of the principal amount of
the Investment as is prescribed in Section 1.1 above.

 

(c)Following the Closing the Company
shall deliver additional Notes and Warrants if provided for in this Agreement.

 

1.4Change of Control. Notwithstanding
anything to the contrary set forth in this Agreement, in the event of a “Change of Control” of VGLS, Investor shall
be entitled to receive (prior to the close of any such Change of Control) any remaining Notes for the full value of the Services
that MDC would have provided to VGLS hereunder during the full term of this Agreement absent such Change of Control, and the Shares
to which Investor would have been entitled to under the Notes or the conversion thereof absent such Change of Control. In addition
to the foregoing, in the event of a Change of Control of VGLS, Investor shall be entitled to receive and exercise (prior to the
close of any such Change of Control) any and all corresponding Warrants to which it would have been entitled under Sections 1.1
and 1.2 above during the full term of this Agreement absent such Change of Control, and the Shares exercisable under the Warrants.
For purposes of this Section 1.4 a “Change in Control” shall mean; (a) the closing of the sale, transfer or other disposition
of all or substantially all of the VGLS’s assets, (b) the consummation of the merger or consolidation of VGLS with or into
another entity (except a merger or consolidation in which the holders of capital stock of VGLS immediately prior to such merger
or consolidation continue to hold at least fifty percent (50%) of the voting power of the capital stock of VGLS or the surviving
or acquiring entity), or any transaction or series of transactions to which VGLS is a party in which in excess of fifty percent
(50%) of VGLS’s voting power is transferred, or (c) the exclusive license of all or substantially all of the intellectual
property of VGLS to a third party.

 

2.Representations, Warranties, and
Covenants of the Company. The Company hereby represents and warrants to the Investor that:

 

2.1Organization, Good Standing and
Qualification. The Company is a corporation duly organized, validly existing and in good standing under the laws of the State
of Delaware and has all requisite corporate power and authority to carry on its business as now conducted and proposed to be conducted.
The Company is duly qualified to transact business and is in good standing in each jurisdiction in which the failure to so qualify
would have a material adverse effect on its business or properties.

 

2.2Authorization. All corporate
actions on the part of the Company, its officers, directors and stockholders necessary for the authorization, execution and delivery
of this Agreement, the performance of all obligations of the Company hereunder and the authorization, issuance and delivery of
the Notes and the Warrants have been taken or will be taken prior to the Closing. This Agreement constitutes, and the Notes and
the Warrants when executed and delivered in accordance with their terms will constitute, valid and legally binding obligations
of the Company, enforceable in accordance with their respective terms except (i) as limited by applicable bankruptcy, insolvency,
reorganization, moratorium, and other laws of general application affecting enforcement of creditors' rights generally, (ii) as
limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies and (iii) as
limited by applicable usury laws.

 

    	2

    	 

    

 

 

2.3Compliance with Other Instruments.
The Company is not in violation or default of any provisions of its Articles of Incorporation, as amended (the "Articles"),
or Bylaws (the "Bylaws"), or, except as set forth on Schedule 1 hereof, in any material respect of any provision
of a mortgage, indenture, agreement, instrument or contract to which it is a party or by which it is bound or of any federal or
state judgment order, writ or decree, or, to its knowledge, of any statute, rule or regulation applicable to the Company. The execution,
delivery and performance by the Company of this Agreement, and the consummation of the transactions contemplated hereby, including
the issuance and delivery of the Notes and the Warrants, will not result in any such violation or be in material conflict with
or constitute, with or without the passage of time or giving of notice, either a material default under any such provision or an
event that results in the creation of any material lien, charge or encumbrance upon any assets of the Company or the suspension,
revocation, impairment, forfeiture, or nonrenewal of any material permit, license, authorization, or approval applicable to the
Company, its business or operations, or any of its assets or properties.

 

2.4Governmental Consents. Based
in part upon the representations and warranties of the Investor in Section 3, no consent, approval, order or authorization
of, or registration, qualification, designation, declaration or filing with, any federal, state or local governmental authority
on the part of the, Company is required in connection with the consummation of the transactions contemplated by this Agreement,
except such post-closing filings as may be required under applicable federal and state securities laws, which will be timely filed
within the applicable period therefor.

 

2.5Sufficient Authorized Shares.
The number of authorized but unissued shares of the Company's Common Stock will be sufficient to permit conversion of the Notes
and the exercise of the Warrants. From the date hereof, the Company shall at all times maintain a sufficient quantity of authorized
but unissued shares of Common Stock sufficient to permit conversion of the Notes and the exercise of the Warrants. In the event
the Company, for any reason, no longer has a sufficient number of authorized but unissued shares to comply with this Section 2.5,
it shall use its best efforts to promptly authorize such shares. Upon the issuance of shares of Common Stock pursuant to the conversion
of the Notes and/or the exercise of the Warrants, such shares of Common Stock shall be duly and validly issued, fully paid and
nonassessable, and issued in compliance with all applicable securities laws, as then in effect, of the United States and each of
the states whose securities laws govern the issuance of the Notes and/or the Warrants pursuant to this Agreement and shall not
be issued in violation of any preemptive or similar right.

 

2.6No Brokers. No broker or finder
has acted directly or indirectly for the Company in connection with the transactions contemplated by this Agreement, and no broker
or finder is entitled to any brokerage, finder's or other fee or commission in respect thereof based in any way on agreements,
arrangements or understandings made by or on behalf of the Company and the Investor or the transactions contemplated hereby.

 

    	3

    	 

    

 

 

2.7Minute Books. The Company has
made available to the Investor (and will continue to make available up to the Closing) copies of the minute books of the Company.
The minute books contains records of all written actions and meetings of the Board of Directors and there have been no written
actions or meetings of the Board of Directors since the date of the last meeting in the minute books.

 

3.Representations and Warranties
of the Investor. The Investor represents and warrants severally and not jointly, with respect to the Investor, that:

 

3.1Authorization. The Investor
has full capacity, power and authority to enter into and perform this Agreement, and all actions necessary to authorize the execution,
delivery and performance of this Agreement have been taken prior to the Closing. This Agreement constitutes a valid and legally
binding obligation of the Investor, enforceable in accordance with its terms, except as the same may be limited by bankruptcy,
insolvency, moratorium, and other laws of general application affecting the enforcement of creditors' rights generally.

 

3.2Receipt of Information. The
Investor believes it, he or she has received all the information necessary or appropriate for deciding whether to acquire the Securities.
The Investor further represents that the Investor has had an opportunity to ask questions and receive answers from the Company
regarding the terms and conditions of the offering of the Securities.

 

3.3Investment Experience. The Investor
is an investor in securities of companies in the development stage and acknowledges that the Investor is able to fend for itself,
herself or himself, can bear the economic risk of its, his or her investment and has such knowledge and experience in financial
or business matters that the Investor is capable of evaluating the merits and risks of the investment in the Securities. If other
than an individual, the Investor also represents it has not been organized for the purpose of acquiring the Securities. The Investor
further represents that the information provided on Investor's counterpart signature page is true and accurate.

 

3.4Restricted Securities. The Investor
understands that the Securities are characterized as "restricted securities" under the federal securities laws inasmuch
as they are being acquired from the Company in a transaction not involving a public offering and that under such laws and applicable
regulations such securities may be resold without registration under the Securities Act of 1933, as amended (the "Securities
Act") only in certain limited circumstances. In connection therewith, each lender represents that it is familiar with Rule 144
under the Securities Act, as presently in effect, and understands the resale limitations imposed thereby and by the Securities
Act.

 

3.5Legends. To the extent applicable,
each certificate or other document evidencing any of the Securities shall be endorsed with the legend set forth below, and the
Investor covenants that, except to the extent such restrictions are waived by the Company, the Investor shall not transfer the
Securities represented by any such certificate without complying with the restrictions on transfer described in the legends endorsed
on such certificate:

 

    	4

    	 

    

 

 

"THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED, OR HYPOTHECATED ABSENT AN EFFECTIVE
REGISTRATION THEREOF UNDER SUCH ACT OR COMPLIANCE WITH RULE 144 PROMULGATED UNDER SUCH ACT, OR UNLESS THE COMPANY HAS RECEIVED
AN OPINION OF COUNSEL, SATISFACTORY TO THE COMPANY AND ITS COUNSEL, THAT SUCH REGISTRATION IS NOT REQUIRED."

 

4.Conditions of Investor's Obligations.
The obligations of the Investor hereunder are subject to the fulfillment on or before the Closing of each of the following conditions:

 

4.1Representations and Warranties.
The representations and warranties of the Company contained in Section 2 shall be true on and as of the Closing with the same
effect as though such representations and warranties had been made on and as of the date of such Closing.

 

4.2Performance. The Company shall
have performed and complied with all agreements, obligations and conditions contained in this Agreement that are required to be
performed or complied with by it on or before the Closing.

 

4.3Board Actions. The Company shall
have delivered to the Investor resolutions duly adopted by the Company's Board of Directors and, to the extent required by applicable
law or by the Company's Articles of Incorporation, the Company's Shareholders, and certified by the Secretary of the Company (i) approving
and authorizing the Company's execution and delivery of this Agreement, the Notes and the Warrants, and the Company's performance
thereunder, and (ii) authorizing the reservation of a sufficient number of shares of the Company's Common Stock to permit
the conversion of the Notes and to permit the exercise of the Warrants.

 

5.Conditions of the Company's Obligations.
The obligations of the Company with respect to the Investor under this Agreement are subject to the fulfillment on or before the
Closing of each of the following conditions:

 

5.1Representations and Warranties.
The representations and warranties of the Investor contained in Section 3 and on the Investor's signature page shall be true
on and as of the Closing with the same effect as though such representations and warranties had been made on and as of the Closing.

 

    	5

    	 

    

 

 

5.2Delivery of Principal. The Investor
shall have delivered the principal amount of the Investor's Investment as is prescribed in Section 1.1.

 

6.Post-Closing Covenant of Company.
During such times as any Note is outstanding, the Company shall provide the Investor with a weekly update of the Company's actual
and forecasted cash position and of any reasonably significant development related to the Company or its business. Such weekly
updates shall be transmitted to the Investor via facsimile or via e-mail, at a facsimile number or e-mail address provided by the
Investor, no later than noon pacific time each Monday during which such obligation remains in effect.

 

7.Reimbursement for Legal Fees.

 

The Company shall reimburse Investor for the
legal fees and administrative costs incurred by it in connection with the transactions contemplated by this Agreement in an amount
not to exceed Ten Thousand Dollars ($10,000).

 

8.Events of Default.

 

Upon the occurrence of any of the following
specified events (each an "Event of Default"), unless such Event of Default shall have been waived or cured prior to
the exercise of the remedies set forth below:

 

8.1Payments. Any default by the
Company in the payment when due of any principal and unpaid accrued interest under any Note if such default is not cured by the
Company within ten (10) days after the holder of such Note has given the Company written notice of such default;

 

8.2Representations and Warranties.
Any representation or warranty made by the Company herein shall prove to have been incorrect in any material respect on or as of
the date made and remains unremedied for a period of thirty (30) days after any Investor provides the Company with written
notice of such breach;

 

8.3Post Closing Covenants. The
failure of Company to satisfy any of the post-closing covenants set forth in Section 6 hereof within the time-periods set
forth therein.

 

8.4Institution of Bankruptcy Proceedings.
The institution by the Company of proceedings to be adjudicated as bankrupt or insolvent, or the consent by it to institution of
bankruptcy or insolvency proceedings against it or the filing by it of a petition or answer or consent seeking reorganization or
release under the federal Bankruptcy Act, or any other applicable federal or state law, or the consent by it to the filing of any
such petition or the appointment of a receiver, liquidator, assignee, trustee, or other similar official, of the Company, or of
any substantial part of its property, or the making by it of an assignment for the benefit of creditors, or the taking of corporate
action by the Company in furtherance of any such action; or

 

8.5Continuation of Bankruptcy Proceedings.
If, within thirty (30) days after the commencement of an action against the Company (and service of process in connection
therewith on the Company) seeking any bankruptcy, insolvency, reorganization, liquidation, dissolution or similar relief under
any present or future statute, law or regulation, such action shall not have been resolved in favor of the Company or all orders
or proceedings thereunder affecting the operations or the business of the Company stayed, or if the stay of any such order or proceeding
shall thereafter be set aside, or if, within thirty (30) days after the appointment without the consent or acquiescence of
the Company of any trustee, receiver or liquidator of the Company or of all or any substantial part of the properties of the Company,
such appointment shall not have been vacated;

 

    	6

    	 

    

 

 

Then, and in any such event, and at any time thereafter, if
any events shall be continuing, the Investor shall have the option to declare the principal amount of the Notes, and all accrued
but unpaid interest thereon, to be immediately due and payable upon written notice to the Company.

 

9.Miscellaneous.

 

9.1Successors and Assigns. Except
as otherwise provided herein, the terms and conditions of this Agreement shall inure to the benefit of and be binding upon the
respective successors and assigns of the parties (including transferees of any securities). Nothing in this Agreement, express
or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights,
remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.

 

9.2Governing Law. This Agreement
shall be governed by and construed under the laws of the State of California, without giving effect to principles of conflict of
laws.

 

9.3Counterparts. This Agreement
may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute
one and the same instrument.

 

9.4Titles and Subtitles. The titles
and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this
Agreement.

 

9.5Notices. Unless otherwise provided,
any notice required or permitted under this Agreement shall be given in writing and shall be deemed effectively given upon personal
delivery to the party to be notified or four (4) days after deposit with the United States Post Office, by registered or certified
mail, postage prepaid and addressed to the party to be notified at the address indicated for such party on the signature page hereof,
or at such other address as such party may designate by advance written notice to the other parties.

 

9.6Finder's Fee. Each party represents
that it neither is nor will be obligated for any finders' fee or commission in connection with this transaction.

 

9.7Entire Agreement. This Agreement
and the other documents delivered pursuant hereto constitute the entire agreement among the parties and no party shall be liable
or bound to any other party in any manner by any warranties, representations, or covenants except as specifically set forth herein
or therein.

 

    	7

    	 

    

 

 

9.8Amendment and Waiver. Any term
of this Agreement may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular
instance and either retroactively or prospectively), with the written consent of the Company and the Investor. This provision shall
not affect the amendment and waiver provisions of the Note. Any waiver or amendment effected in accordance with this section shall
be binding upon each holder of any Securities purchased under this Agreement at the time outstanding, each future holder of all
such Securities, and the Company.

 

9.9Severability. If one or more
provisions of this Agreement are held to be unenforceable under applicable law, such provision shall be excluded from this Agreement
and the balance of the Agreement shall be interpreted as if such provision were so excluded and shall be enforceable in accordance
with its terms.

 

9.10Survival. The representations,
warranties, covenants and agreements made herein shall survive the Closing for a period of 12 months.

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

 

    	8

    	 

    

 

IN WITNESS WHEREOF, the parties have executed
this Agreement as of the date first above written.

 

 

VG Life Sciences Inc.

 

 

/s/ Haig Keledjian 

By: Haig Keledjian

Title: Chairman

 

 

MedBridge Venture Fund, LLC,

by its Managers:

 

 

Wild Harp Holdings, LLC

 

 

/s/ John P. Tynan

By: John P. Tynan, its Manager

 

 

DW Odell Company, LLC

 

 

/s/ David W. Odell

By: David W. Odell, Manager

 

 

    	9

    	 

    

 

EXHIBIT A

 

VG LIFE SCIENCES, INC.

CONVERTIBLE PROMISSORY NOTE

 

THIS CONVERTIBLE PROMISSORY
NOTE (“Note”) is issued as of January 15, 2015 (the “Original Issue Date”), by VG Life Sciences, Inc.,
a Delaware corporation (the “Company”), in an aggregate principal amount of $862,500.

 

Terms not otherwise defined
herein shall have the meanings given in Section 6 below.

 

FOR VALUE RECEIVED, the
Company promises to pay to MedBridge Venture Fund, LLC, or registered assigns (the “Holder”), the principal sum of
Eight Hundred Sixty Two Thousand and Five Hundred Dollars ($862,500) on or before December 31, 2015 (the “Maturity Date”)
and to pay interest to the Holder on the principal sum, at the rate per annum of eight percent (8%). Interest shall accrue daily
commencing on the Original Issue Date until payment in full of the principal sum, together with all accrued and unpaid interest,
has been made or duly provided for. Interest shall be calculated on the basis of a 360-day year. Interest hereunder will be due
and payable at the Maturity Date, to the person in whose name this Note is registered on the records of the Company (the “Note
Register”). The principal of, and interest on, this Note are payable in such coin or currency of the United States of America
as at the time of payment is legal tender for payment of public and private debts, at the address of the Holder last appearing
on the Note Register. A transfer of the right to receive principal and interest under this Note shall be transferable only through
an appropriate entry in the Note Register as provided herein.

 

This Note is subject to
the following additional provisions:

 

Section 1. Convertible
Note and Warrant Purchase Agreement. This Note is one of the Notes issued pursuant to that certain Convertible Note and Warrant
Purchase Agreement (the “Agreement”) between the Company and Holder dated as of January 12, 2015 This Note is subject
to, and qualified by, all the terms and conditions set forth in the Agreement.

 

Section 2. Events
of Default.

 

Section 2.1 Events
of Default Defined; Acceleration of Maturity. If an Event of Default (as defined in the Agreement) has occurred then upon the
occurrence of any such Event of Default, the Holder may, by notice to the Company, declare the unpaid principal amount of the Notes
to be, and the same shall forthwith become, due and payable, without presentment, demand, protest or other notice of any kind,
all of which are hereby waived by the Company, together with the interest accrued thereon and all other amounts payable by the
Company hereunder and pursue all of Holder’s rights and remedies hereunder and under the other Loan Documents and all other
remedies available to Holder under applicable law.

 

    	A-1

    	 

    

 

Section 3. Optional
Conversion.

 

(a) The outstanding principal
and all accrued and unpaid interest of this Note shall be convertible, at the option of the Holder, into shares of common stock
of the Company (“Common Stock”) at the Conversion Ratio, at the option of the Holder, in four equal tranches (25% each)
on the following dates: March 31, 2015, June 30, 2015, September 30, 2015, and December 31, 2015. Any conversion under this Section
3(a) shall be of a minimum amount of US $5,000 of Notes. The Holder shall effect conversions by surrendering the Notes (or
such portions thereof) to be converted to the Company, together with the form of conversion notice attached hereto as Exhibit
A (the “Conversion Notice”) in the manner set forth in Section 3(h). Each Conversion Notice shall specify
the principal amount of Notes to be converted and the date on which such conversion is to be effected (the “Conversion Date”).
Subject to Section 3(b), each Conversion Notice, once given, shall be irrevocable. If the Holder is converting less than
all of the principal amount represented by the Note(s) tendered by the Holder with the Conversion Notice, the Company shall promptly
deliver to the Holder a new Note for such principal amount as has not been converted.

 

(b) Not later than fifteen
(10) Business Days after the Conversion Date, the Company will deliver to the Holder (i) a certificate or certificates containing
the restrictive legends and trading restrictions required by law, if any, representing the number of shares of Common Stock being
acquired upon the conversion of Notes and (ii) Notes in principal amount equal to the principal amount of Notes not converted;
provided, however that the Company shall not be obligated to issue certificates evidencing the shares of Common Stock issuable
upon conversion of any Notes, until Notes are either delivered for conversion to the Company or any transfer Holder for the Notes
or Common Stock, or the Holder notifies the Company that such Notes have been lost, stolen or destroyed and provides a lost instrument
indemnity to the Company to indemnify the Company from any loss incurred by it in connection therewith. If such certificate or
certificates are not delivered by the date required under this Section 3(b), the Holder shall be entitled by written notice
to the Company at any time on or before its receipt of such certificate or certificates thereafter, to rescind such conversion,
in which event the Company shall immediately return the Notes tendered for conversion.

 

(c) (i) The conversion
price (“Conversion Price”) for each Note in effect on any Conversion Date shall be 10% less than the lowest 3 day average
during the period beginning January 12, 2015 and ending on February 11, 2015, subject to adjustment as otherwise contemplated by
this Section 3(c).

 

(ii) In case of any Acquisition
(as defined below) of the Company, then Holder shall have the right thereafter to convert any principal and interest remaining
owing under this Note prior to the closing of any such Acquisition. At the election of Holder, Holder may convert this Note into
the shares of stock and other securities and property receivable upon or deemed to be held by holders of Common Stock following
such Acquisition, and the Holder shall be entitled upon such event to receive such amount of securities or property as the shares
of the Common Stock, into which the Note could have been converted immediately prior to such Acquisition, would have been entitled.
The terms of any such Acquisition shall include such terms so as to continue to give to the Holder the right to receive the securities
or property set forth in this Section 3(c) upon any conversion following such Acquisition. This provision shall similarly
apply to successive Acquisitions. “Acquisition” means (a) the closing of the sale, transfer or other disposition of
all or substantially all of the VGLS’s assets, (b) the consummation of the merger or consolidation of VGLS with or into another
entity (except a merger or consolidation in which the holders of capital stock of VGLS immediately prior to such merger or consolidation
continue to hold at least fifty percent (50%) of the voting power of the capital stock of VGLS or the surviving or acquiring entity),
or any transaction or series of transactions to which VGLS is a party in which in excess of fifty percent (50%) of VGLS’s
voting power is transferred, or (c) the exclusive license of all or substantially all of the intellectual property of VGLS to a
third party

 

    	A-2

    	 

    

 

(iii) The Conversion Price
shall be subject to adjustment as follows:

 

(A) In case the Company
shall (i) pay a dividend in shares of its capital stock, (ii) subdivide its outstanding shares of Common Stock, (iii) combine its
outstanding shares of Common Stock into a smaller number of shares, or (iv) issue by reclassification of its shares of Common Stock
any shares of the Company, the Conversion Price in effect immediately prior thereto shall be adjusted so that the Holder of this
Note thereafter surrendered for conversion shall be entitled to received the number of shares of Common Stock which he would have
owned or have been entitled to receive after the happening of any of the events described above, had this Note been converted immediately
prior to the happening of such event. Such adjustment shall be made whenever any of the events listed above shall occur. An adjustment
made pursuant to this subdivision (A) shall become effective retroactively immediately after the record date in the case of a dividend
and shall become effective immediately after the effective date in the case of a subdivision, combination or reclassification.

 

(B) If, at any time while
this Note is outstanding, the Company issues Common Stock or other securities convertible into, or exercisable for, Common Stock,
at a price per share of Common Stock equivalent that is less than the Conversion Price (or adjusted Conversion Price if the Conversion
Price has been adjusted previously), then the Conversion Price shall be reduced to an amount equal to the price per share of Common
Stock equivalent in such issuance; provided, however, that any of the following issuances shall not be subject to the provisions
of this subparagraph (B): (i) any borrowings, direct or indirect, from banks or similar financial institutions by the Company,
whether or not presently authorized, including any type of loan or payment evidenced by any type of debt instrument, provided such
borrowings do not have any equity features including warrants, options or other rights to purchase capital stock and are not convertible
into capital stock of the Company; (ii) securities issued to employees, consultants, officers or directors of the Company pursuant
to any stock option, stock purchase or stock bonus plan, agreement or arrangement approved by the Company’s Board of Directors,
provided that the aggregate number of such securities shall not exceed at any time fifteen percent of the then-outstanding Common
Stock of the Company; or (iii) securities issued in a public offering pursuant to a registration under the Securities Act of 1933,
as amended (the “Securities Act”) with an aggregate offering price to the public of at least $50,000,000.

    	A-3

    	 

    

 

 

(C) If, at any time while
this Note is outstanding, the Company takes any voluntary action or any event occurs as to which the foregoing subdivisions (A)
through (D) are not strictly applicable, but the failure to make an adjustment in the Conversion Price hereunder would not fairly
protect the rights, without dilution, represented by this Note, then the Conversion Price in effect immediately prior thereto shall
be adjusted so that the Holder of this Note shall be entitled to receive the number of shares of Common Stock which he would have
owned or been entitled to receive after the happening of any such action or event, had this Note been converted immediately prior
to the happening of any such action or event.

 

(d) The Company covenants
that it will at all times reserve and keep available out of its authorized and unissued Common Stock solely for the purpose of
issuance upon conversion of Notes as herein provided, free from preemptive rights or any other actual contingent purchase rights
of persons other than the holders of Notes, such number of shares of Common Stock as shall be issuable upon the conversion of the
aggregate principal amount of all outstanding Notes. The Company covenants that all shares of Common Stock that shall be so issuable
shall, upon issue, be duly and validly authorized, issued and fully paid and nonassessable.

 

(e) Upon a conversion hereunder
the Company shall not be required to issue stock certificates representing fractions of shares of Common Stock, but may, if otherwise
permitted, make a cash payment in respect of any final fraction of a share based on the Conversion Price at such time.

 

(f) The issuance of certificates
for shares of Common Stock on conversion of Notes shall be made without charge to the Holder for any documentary stamp or similar
taxes that may be payable in respect of the issue or delivery of such certificate, provided that the Company shall not be required
to pay any tax that may be payable in respect of any transfer involved in the issuance and delivery of any such certificate upon
conversion in a name other than that of the Holder and the Company shall not be required to issue or deliver such certificates
unless or until the person or persons requesting the issuance thereof shall have paid to the Company the amount of such tax or
shall have established to the satisfaction of the Company that such tax has been paid.

 

(g) Notes converted into
Common Stock shall be canceled.

 

(h) Each Conversion Notice
shall be given by facsimile and by mail, postage prepaid, addressed to the Controller of the Company of VG Life Sciences, Inc.
located 121 Gray Avenue, Suite 200, Santa Barbara, CA 93101. Any such notice shall be deemed given and effective upon the earliest
to occur of (i) receipt of such facsimile at the facsimile telephone number specified in this Section 3(h), (ii) five days
after deposit in the United States mails or (iii) upon actual receipt by the party to whom such notice is required to be given.

 

 

    	A-4

    	 

    

Section 4. Mandatory Conversion.

 

(a) In the event Holder
has not elected to convert all of the principal and interest remaining owing under this Note on or prior to one year after the
date of this note, the then outstanding principal and accrued and unpaid interest amount of this Note shall, without further action
by the Holder or the Company, be automatically converted in whole into that number of shares of Common Stock of the Company at
the Conversion Ratio on the Maturity Date (the “Mandatory Conversion Date”).

 

(b) Not later than ten
(10) Business Days after the Mandatory Conversion Date, the Company will deliver to the Holder a certificate or certificates containing
the restrictive legends and trading restrictions required by law, if any, representing the number of shares of Common Stock being
acquired upon the mandatory conversion of this Note; provided, however that the Company shall not be obligated to issue
certificates evidencing the equity securities issuable upon conversion of this Note, until the Note is either delivered for conversion
to the Company or any transfer Holder of the Note or Common Stock, or the Holder notifies the Company that the Note have been lost,
stolen or destroyed and provides a lost instrument indemnity or bond to the Company to indemnify the Company from any loss incurred
by it in connection therewith. The Company covenants and agrees that it shall comply with Sections 3(d) through (g)
with respect to any mandatory conversion and such sections are incorporated by reference herein.

 

Section 5. Payment
of Principal and Redemption.

 

(a) In the event of an occurrence
of an Event of Default, then the outstanding principal balance of this Note shall be due and payable in full on the Maturity Date.
Prior to the Mandatory Conversion Date this Note may not be prepaid.

 

(b) Nothing in this Section
5 shall impair the Holder’s right to convert this Note pursuant to Section 3 prior to the Mandatory Conversion Date.

 

Section 6. Definitions.
For the purposes hereof, the following terms shall have the following meanings:

 

“Business Day”
shall mean any day, except a Saturday, Sunday or other day on which commercial banks in the State of California are authorized
or required by law to close.

 

“Conversion Ratio”
means, at any time, a fraction, of which the numerator is the outstanding principal amount represented by any Note plus accrued
but unpaid interest, and of which the denominator is the Conversion Price at such time.

 

“Original Issue Date”
means the date of the first issuance of this Note regardless of the number transfers hereof.

 

    	A-5

    	 

    

 

Section 7. Stockholder
Rights. This Note shall not entitle the Holder to any of the rights of a stockholder of the Company, including without limitation,
the right to vote, to receive dividends and other distributions, or to receive any notice of, or to attend, meetings of stockholders
or any other proceedings of the Company, unless and to the extent converted into shares of Common Stock in accordance with the
terms hereof.

 

Section 8. Lost
Note. If this Note shall be mutilated, lost, stolen or destroyed, the Company shall execute and deliver, in exchange and substitution
for and upon cancellation of a mutilated Note, or in lieu of or in substitution for a lost, stolen or destroyed debenture, a new
Note for the principal amount of this Note so mutilated, lost, stolen or destroyed but only upon receipt of evidence of such loss,
theft or destruction of such Note, and of the ownership hereof, and indemnity or bond, if requested, all reasonably satisfactory
to the Company.

 

Section 9. Governing
Law. This Note shall be governed by and construed in accordance with the laws of the State of California, without giving effect
to conflicts of laws thereof.

 

Section 10. Notices.
All notices or other communications hereunder shall be given, and shall be deemed duly given and received, if given, in the manner
set forth in Section 5(h).

 

Section 11. Waiver.
Any waiver by the Company or the Holder a breach of any provision of this Note shall not operate as or be construed to be a waiver
of any other breach of such provision or of any breach of any other provision of this Note. The failure of the Company or the Holder
to insist upon strict adherence to any term of this Note on one or more occasions shall not be considered a waiver or deprive that
party of the right thereafter to insist upon strict adherence to that term or any other term of this Note. Any waiver must be in
writing.

 

Section 12. Severability.
If any provision of this Note is invalid, illegal or unenforceable, the balance of this Note shall remain in effect, and if any
provision is inapplicable to any person or circumstance, it shall nevertheless remain applicable to all other persons and circumstances.

    	A-6

    	 

    

 

IN WITNESS WHEREOF, the Company has caused this
instrument to be duly executed by an officer thereunto duly authorized as of the date first above indicated.

 

	 	VG LIFE SCIENCES, INC.,
	 	a Delaware corporation
	 	 
	 	 
	 	 
	 	By:       ______________________________
	 	Name:     John P. Tynan
	 	Title:     President & CEO

 

 

    	A-7

    	 

    

EXHIBIT A

 

 

 

NOTICE OF CONVERSION

AT THE ELECTION OF HOLDER

 

(To be Executed by the Registered Holder

in order to Convert the Note)

 

The undersigned hereby irrevocably elects to
convert the above Note into shares of Common Stock, no par value per share (the “Common Stock”), of VG Life Sciences,
Inc. (the “Company”) according to the conditions hereof, as of the date written below. If shares are to be issued in
the name of a person other than undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering
herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged
to the Holder for any conversion, except for such transfer taxes, if any.

 

 

 

	Conversion calculations:	 
	 	Date to Effect Conversion
	 	 
	 	 
	 	Principal Amount of Notes to be Converted
	 	 
	 	 
	 	Applicable Conversion Price
	 	 
	 	 
	 	Signature 
	 	 
	 	 
	 	Name:
	 	 
	 	 
	 	Address:

 

    	A-8

    	 

    

 

 

Schedule of Services from MedBridge Venture
Fund

For the Benefit of VG Life Sciences, Inc.

 

 

	January 12-31, 2015 (prorated)	$37,500
	 	 
	February 28, 2015	$75,000
	 	 
	March 31, 2015	$75,000
	 	 
	April 30, 2015	$75,000
	 	 
	May 31, 2015	$75,000
	 	 
	June 30, 2015	$75,000
	 	 
	July 31, 2015 	$75,000
	 	 
	August 31, 2015	$75,000
	 	 
	September 30, 2015	$75,000
	 	 
	October 31, 2015	$75,000
	 	 
	November 30, 2015	$75,000
	 	 
	December 31, 2015	$75,000

 

 

 

    	A-9

    	 

    

 

EXHIBIT B

 

WARRANT TO PURCHASE STOCK

 

Company: VG Life Sciences, Inc.

Number of Shares: 3,450,000

Class of Stock: Common

Initial Exercise Price Per Share: $0.45

Issue Date: January 15, 2015

 

THIS WARRANT CERTIFIES
THAT, for the agreed upon value of $1.00 and for other good and valuable consideration, MedBridge Venture Fund, LLC, a California
limited liability company (“Holder”) is entitled to purchase the number of fully paid and nonassessable shares of the
class of securities (the “Shares”) of VG Life Sciences, Inc. (the “Company” or “VGLS”) at the
initial exercise price per Share (the “Warrant Price”) all as set forth above and as adjusted pursuant to Article 2
of this Warrant, subject to the provisions and upon the terms and conditions set forth of this Warrant.

 

ARTICLE 1. EXERCISE

 

1.1Method of Exercise. Holder
may exercise this Warrant by delivering a duly executed Notice of Exercise is substantially the form attached as Appendix 1 to
the principal office of the Company. Unless Holder is exercising the conversion right set forth in Section 1.2, Holders shall also
deliver to the Company a check for the aggregate Warrant Price for the Shares being purchased.

 

1.2Conversion Right. In lieu
of exercising this Warrant as specified in Section 1.1, Holder may from time to time convert this Warrant, in whole or in part,
into a number of Shares determined by dividing (a) the aggregate fair market value of the Shares or other securities otherwise
issuable upon exercise of this Warrant minus the aggregate Warrant Price of such Shares by (b) the fair market value of one Share.
The fair market value of the Shares shall be determined pursuant Section 1.4.

 

1.3No Rights Shareholder. This
Warrant does not entitle Holder to any voting rights as a shareholder of the company prior to the exercise hereof.

 

1.4Fair Market Value. For purposes
of Section 1.2, if the Shares are traded in a public market, the fair market value of the Shares shall be the closing price of
the Shares (or the closing price of the Company’s stock into which the Shares are convertible) reported for the business
day immediately before Holder delivers its Notice of Exercise to the Company. If the Shares are not traded in a public market,
the Board of Directors of the Company shall determine fair market value in its reasonable good faith judgment. The foregoing notwithstanding,
if Holder advises the Board of Directors in writing that Holder disagrees with such determination, then the Company and Holder
shall promptly agree upon a reputable investment banking or public accounting firm to undertake such valuation. If the valuation
of such investment banking firm is greater than that determined by the Board of Directors, then all fees and expenses of such investment
banking firm shall be paid by the company. In all other circumstances, such fees and expenses shall be paid by Holder.

 

    	B-1

    	 

    

 

1.5Delivery of Certificate and New
Warrant. Promptly after Holder exercises or converts this Warrant, the Company shall deliver to Holder certificates for the
Shares acquired and, if this Warrant has not been fully exercised or converted and has not been fully exercised or converted and
has not expired, a new Warrant representing the Shares not so acquired.

 

1.6 Replacement of Warrants.
On receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant and,
in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory in form and amount to
the Company or, in the case of mutilation, or surrender and cancellation of this Warrant, the Company at its expense shall execute
and deliver, in lieu of this Warrant, a new warrant of like tenor.

 

1.7Repurchase on Sale, Merger, or
Consolidation of the Company

 

1.7.1“Acquisition” 
For the purpose of this Warrant, “Acquisition” means (a) the closing of the sale, transfer or other disposition of
all or substantially all of the VGLS’s assets, (b) the consummation of the merger or consolidation of VGLS with or into another
entity (except a merger or consolidation in which the holders of capital stock of VGLS immediately prior to such merger or consolidation
continue to hold at least fifty percent (50%) of the voting power of the capital stock of VGLS or the surviving or acquiring entity),
or any transaction or series of transactions to which VGLS is a party in which in excess of fifty percent (50%) of VGLS’s
voting power is transferred, or (c) the exclusive license of all or substantially all of the intellectual property of VGLS to a
third party.

 

1.7.2Assumption of Warrant.
Upon the closing of any Acquisition the successor entity shall assume the obligations of this Warrant, and this Warrant shall be
exercisable for the same securities, cash, and property as would be payable for the Shares issuable upon exercise of the unexercised
portion of this Warrant as if such Shares were outstanding on the record date for the Acquisition and subsequent closing. The Warrant
Price shall be adjusted accordingly.

 

1.7.3Purchase Right. Notwithstanding
the foregoing, at the election of Holder, the Company shall purchase the unexercised portion of this Warrant for cash upon the
closing of any Acquisition for an amount equal to (a) the fair market value of any consideration that would have been received
by Holder in consideration of the Shares had Holder exercised the unexercised portion of this Warrant immediately before the record
date for determining the shareholders entitled to participate in the proceeds of the Acquisition, less (b) the aggregate Warrant
Price of the Shares, but in no event less than zero.

 

ARTICLE 2. ADJUSTMENTS TO THE SHARES.

 

2.1Stock Dividends, Splits, Etc.
If the Company declares or pays a dividend on its common stock ( or the Shares if the Shares are securities other than common stock
) payable in common stock, or other securities, subdivides the outstanding common stock into a greater amount of common stock,
or, if the Shares are securities other than common stock, subdivides the Shares in a transaction that increases the amount of common
stock into which the Shares are convertible, then upon exercise of this Warrant, for each Share acquired, Holder shall receive,
without cost to Holder, the total number and kind of securities to which Holder would have been entitled had Holder owned the Shares
of record as of the date the dividend or subdivision occurred.

 

    	B-2

    	 

    

 

2.2Reclassification, Exchange or
Substitution. Upon any reclassification, exchange, substitution, or other event that results in a change of the number and/or
class of the securities issuable upon exercise or conversion of this Warrant, Holder shall be entitled to receive, upon exercise
or conversion of this Warrant, the number and kind of securities and property that Holder would have received for the shares if
this Warrant had been exercised immediately before such reclassification, exchange, substitution, or other event. Such an event
shall include any automatic conversion of the outstanding or issuable securities of the Company of the same class or series as
the Shares to common stock pursuant to the terms of the Company’s Certificate of Incorporation upon the closing of a registered
public offering of the Company’s common stock. The Company or its successor shall promptly issue to Holder a new Warrant
for such new securities or other property. The new adjustments provided for in this Article 2 including, without limitation, adjustments
to the Warrant Price and to the number of securities or property issuable upon exercise of the new Warrant. The provisions of this
Section 2.2 shall similarly apply to successive reclassifications, exchanges, substitutions, or other events.

 

2.3Adjustments for Combinations,
Etc. If the outstanding Shares are combined or consolidated, by reclassification or otherwise, into a lesser number of shares,
the Warrant price shall be proportionately increased.

 

2.4Adjustments for Diluting Issuances.
The number of shares of common stock issuable upon conversion of the Shares, shall be subject to adjustment, from time to time
in the manner set forth in the Company’s Certificate of Incorporation with respect to issuance of securities for a price
lower than certain prices specified in the Certificate of Incorporation.

 

2.5No Impairment. The Company
shall not, by amendment of its Certificate of Incorporation or through a reorganization, transfer of assets, consolidation, merger,
dissolution, issue, or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of
any of the terms to be observed or performed under this Warrant by the Company, but shall at all times in good faith assist in
carrying out of all the provisions of this Article 2 and in taking all such action as may be necessary or appropriate to protect
Holder’s rights under this Article against impairment. If the Company takes any action affecting the Shares or its common
stock other than as described above that adversely affects Holder’s rights under this Warrant, the Warrant Price shall be
adjusted downward and the number of Shares issuable upon exercise of this Warrant shall be adjusted upward in such a manner that
the aggregate Warrant price of this Warrant is unchanged.

 

2.6Fractional Shares.  No fractional
Shares shall be issuable upon exercise or conversion of the Warrant and the number of Shares to be issued shall be rounded down
to the nearest whole Share. If a fractional share interest arises upon any exercise or conversion of the Warrant, the Company shall
eliminate such fractional share interest by paying Holder amount computed by multiplying the fractional interest by the fair market
value of a full Share.

 

    	B-3

    	 

    

 

2.7Certificate as to Adjustments.
Upon each adjustment of the Warrant Price, the Company at its expense shall promptly compute such adjustment, and furnish Holder
with a certificate of its Chief Financial officer setting forth such adjustment and the facts upon which such adjustment is based.
The Company shall, upon written request, furnish Holder a certificate setting forth the Warrant price in effect upon the date thereof
and the series of adjustments leading to such Warrant Price.

 

ARTICLE 3. REPRESENTATIONS AND COVENANTS
OF THE COMPANY.

 

3.1Representations and Warranties.
The Company hereby represents and warrants to the Holder that all Shares which may be issued upon the exercise of the purchase
right represented by this Warrant and all securities, if any, issuable upon conversion of the Shares, shall, upon issuance, be
duly authorized, validly issued, fully paid and nonassessable, and free of any liens and encumbrances except for restrictions on
transfer provided for herein or under applicable federal and state securities laws.

 

3.2 Notice of Certain Events.
If the company proposes at any time (a) to declare any dividend or distribution upon its common stock, whether in cash, property,
stock or other securities and whether or not a regular cash dividend; (b) to offer for subscription pro rata to the holders of
any class or series or other rights; (c) to effect any reclassification or recapitalization of common stock; (d) to merge or consolidate
with or into any other corporation, or sell, lease, license, or convey all or substantially all of its assets, or to liquidate,
dissolve or wind up; or (e) offer holders of registration rights the opportunity to participate in an underwritten public offering
of the company’s securities for cash, then, in connection with each such event, the Company shall give Holder (1) at least
20 days prior written notice of the date on which a record will be taken for such dividend, distribution or subscription rights
(and specifying the date on which the holders of common stock will be entitled thereto) or for determining rights to vote, if any,
in respect of the matters referred to in (c) and (d) above; 2 in the case of the matters referred to in (c) and (d) above at least
20 days prior written notice of the date when the same will take place (and specifying the date on which the holders of common
stock will be entitled to exchange their common stock for securities or other property deliverable upon the occurrence of such
event); and (3) in the case of the matter referred to in (e) above, the same notice as is given to the holders of such registration
rights.

 

3.3Information Rights. So long
as the Holder holds this Warrant and /or any of the Shares, the Company shall deliver to the Holder (a) promptly after mailing,
copies of all notices or other written communications to the shareholders of the Company, (b) within ninety (90) days after the
end of each fiscal year of the Company, the annual financial statements of the Company.

    	B-4

    	 

    

 

 

3.4Registration Under Securities
Act of 1933, as amended.  The Company agrees that the Shares shall be subject to the registration rights granted to any other
holders of the Company’s common stock.

 

ARTICLE 4. MISCELLANEOUS.

 

4.1Term. This Warrant is exercisable,
in whole or in part, at any time and from time to time on or after the fourth anniversary of the Issue Date hereof and up to and
including the fifth anniversary of the Issue Date.

 

4.2Legends.  This Warrant and
the Shares (and the securities issuable, directly or indirectly, upon conversion of the Shares, if any) shall be imprinted with
a legend in substantially the following form:

 

THIS SECURITY HAS NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE SOLD, PLEDGED OR OTHERWISE TRANSFERRED WITHOUT AN
EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT OR PURSUANT TO RULE 144 OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE
CORPORATION AND ITS COUNSEL THAT SUCH REGISTRATION IS NOT REQUIRED.

 

4.3Compliance with Securities Laws
on Transfer. This Warrant and the Shares issuable upon exercise this Warrant (and the securities issuable , directly or indirectly,
upon conversion of the shares, if any) may not be transferred or assigned in whole or in part without compliance with limitation,
the delivery of investment representation letters and legal opinions reasonably satisfactory to the Company, as reasonable requested
by the Company). The Company shall not require Holder to provide an opinion of counsel if the transfer is to an affiliate of Holder
or if there is no material question as to the availability of current information as referenced in rule 144(c), Holder represents
that it has complied with Rule 144(d) and (e) in reasonable detail, the selling broker represents that it has complied with Rule
144(f), and the Company is provided with a copy of Holder’s notice of proposed sale.

 

4.4Transfer Procedure.Subject
to the provisions of Section 4.2, Holder may transfer all or part of this Warrant or the Shares issuable upon exercise of this
Warrant (or the securities issuable, directly or indirectly, upon conversion of the Shares, if any) by giving the Company notice
of the portion of the Warrant being transferred setting forth the name, address and taxpayer identification number of the transferee
and surrendering this Warrant to the company for reissuance to the transferee(s) (and Holder if applicable).

 

4.5Notices. All notices and
other communications from the Company to the Holder, or vice versa, shall be deemed delivered and effective when given personally
or mailed by first-class registered or certified mail, postage prepaid, at such address as may have been furnished to the Company
or the Holder, as the case may be, in writing by the Company or such holder from time to time.

 

    	B-5

    	 

    

 

4.6Waiver. This Warrant and
any term hereof may be changed, waived, discharged or terminated only by an instrument in writing signed by the party against which
enforcement of such change, waiver, discharge or termination is sought.

 

4.7Attorneys Fees. In the event
of any dispute between the parties concerning the terms and provisions of this Warrant, the party prevailing in such dispute shall
be entitled to collect from the other party all costs incurred in such dispute, including reasonable attorney’s fees.

 

4.8Governing Law.  This Warrant
shall be governed by and construed in accordance with the laws of the State of California, without giving effect to its principles
regarding conflicts of law.

 

 

	 	 
	 	______________________________________
	 	 
	 	By: John P. Tynan
	 	 
	 	Title: President & CEO

 

 

    	B-6

    	 

    

 

 

APPENDIX 1

 

 

NOTICE OF EXERCISE

 

 

 

1. The undersigned
hereby elects to convert the attached Warrant into in the manner specified in the Warrant. This conversion is exercised with respect
to _______________________ of the Shares covered by the Warrant.

 

 

2.Please issue a certificate or certificates
representing said shares in the name of the undersigned or in such other name as is specified below:

 

	 
	(Name)
	 
	 
	 
	 
	(Address)

 

3.                 
The undersigned represents it is acquiring the shares solely for its own account and not as a nominee for any other party
and not with a view toward the resale or distribution thereof except in compliance with applicable securities laws.

 

	 	 	 
	(Date)	 	(Signature)

 

 

 

    	B-7

    	 

    

 

 

EXHIBIT C

SERVICES TO BE PROVIDED BY MEDBRIDGE VENTURE
FUND, LLC

 

The following list outlines the services to be provided by MedBridge
Venture Fund, LLC to VG Life Sciences, Inc. for the period beginning January 12, 2015 and ending December 31, 2015 at a value of
$75,000 per month:

 

Management Team including:

 

1.President & CEO (Mr. John Tynan)

 

2.Chief Financial Officer (Mr. Dave
Odell)

 

3.Chief Operating Officer (Ms. Jill
Himlan)

 

4.Controller (Mr. Caleb Rhoads)

 

5.Corporate Project Manager (Mr. Garrett
Johnson)*

Grant Application Coordinator

 

Administrative Assistant, Finance

 

Additional Public Relations Resources

 

* The Corporate Project Manager, Garrett Johnson, shall render services
under this Exhibit C only for the time period of March 15, 2015 through July 31, 2015, but such limited time provision shall no
other effect on any term or condition of this Exhibit C.

 

 

The total value of services to be provided by MedBridge Venture
Fund, LLC to VG Life Sciences, Inc. for the period January 12, 2015 and ending December 31, 2015 is $862,500.

 

 

    	C-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00239-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00239-of-00352.parquet"}]]